Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Asthma
Pharma company submits application to market Aridol in Europe
June 17th, 2005
Specialty pharmaceutical company Pharmaxis Ltd (ASX:PXS) announced that it has submitted the marketing authorization application for its asthma management product Aridol to the Swedish Medicinal Products Agency (MPA), the national authority responsible for the regulation and surveillance of drugs and other medicinal products in Sweden. Authorization can take from 6 to 18 months and, if granted, will allow Pharmaxis to sell Aridol in the 25 member countries of the European Union. Alan Robertson, Pharmaxis chief executive officer said: "This European submission is a further important step in the commercialization of Aridol. Additionally, we have a...
Source: Drug Week (2005-06-17)
|
